title: Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock.
abstract: OBJECTIVE
  Plasma interleukin-8 levels of <220 pg/mL have an excellent negative predictive value (94% to 95%) for death at 28 days in children with septic shock and thus may be useful for risk stratification in clinical trial enrollment in this population. Whether plasma interleukin-8 would have similar utility in adults with septic shock is unknown.
  
  
  METHODS
  Analysis of plasma interleukin-8 levels and prospectively collected clinical data from patients enrolled in two large randomized controlled trials of ventilator strategy for acute lung injury.
  
  
  METHODS
  Intensive care units of university hospitals participating in the National Institutes of Health Acute Respiratory Distress Syndrome Network.
  
  
  METHODS
  One hundred ninety-two adult patients with vasopressor-dependent septic shock.
  
  
  METHODS
  None.
  
  
  RESULTS
  Plasma interleukin-8 levels > or =220 pg/mL were significantly associated with death at 28 days in this cohort (odds ratio, 2.92; 95% confidence interval, 1.42 to 5.99; p = .001). However, in contrast to the findings in pediatric septic shock, a plasma interleukin-8 cutoff <220 pg/mL had a negative predictive value for death of only 74% (95% confidence interval, 66% to 81%) in adults with septic shock. Receiver operating characteristic analysis found an area under the curve of 0.59 for plasma interleukin-8, indicating that plasma interleukin-8 is a poor predictor of mortality in this group. In adults aged <40 yrs, a plasma interleukin-8 cutoff <220 pg/mL had a negative predictive value of 92%.
  
  
  CONCLUSIONS
  In contrast to similar pediatric patients, plasma interleukin-8 levels are not an effective risk stratification tool in older adults with septic shock. Future studies of biomarkers for risk stratification in critically ill subjects will need to be replicated in multiple different populations before being applied in screening for clinical trials.
authors.affiliation: Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, CA, USA. carolyn.calfee@ucsf.edu
authors.forename: Carolyn S
authors.initials: CS
authors.lastname: Calfee
authors.forename: B Taylor
authors.initials: BT
authors.lastname: Thompson
authors.forename: Polly E
authors.initials: PE
authors.lastname: Parsons
authors.forename: Lorraine B
authors.initials: LB
authors.lastname: Ware
authors.forename: Michael A
authors.initials: MA
authors.lastname: Matthay
authors.forename: Hector R
authors.initials: HR
authors.lastname: Wong
mesh_terms: D055371:Acute Lung Injury / Q000097:blood* / Q000150:complications / Q000628:therapy; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D003422:Critical Care; D005260:Female; D006801:Humans; D016209:Interleukin-8 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012372:ROC Curve; D012121:Respiration, Artificial; D018570:Risk Assessment; D012772:Shock, Septic / Q000097:blood* / Q000209:etiology / Q000401:mortality*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D016209:Interleukin-8; D014662:Vasoconstrictor Agents
references.citation: N Engl J Med. 2000 May 4;342(18):1301-8
references.pmid: 10793162
references.citation: Curr Infect Dis Rep. 2006 Sep;8(5):351-7
references.pmid: 16934193
references.citation: Arch Gen Psychiatry. 1983 May;40(5):569-73
references.pmid: 6838334
references.citation: Crit Care. 2007;11(2):R49
references.pmid: 17448250
references.citation: J Intensive Care Med. 2009 May-Jun;24(3):151-67
references.pmid: 19282296
references.citation: Ann Intern Med. 2001 Apr 17;134(8):663-94
references.pmid: 11304107
references.citation: N Engl J Med. 2003 Apr 17;348(16):1546-54
references.pmid: 12700374
references.citation: Crit Care Med. 2009 Jul;37(7):2290-8
references.pmid: 19487943
references.citation: Intensive Care Med. 1995 Sep;21(9):770-6
references.pmid: 8847434
references.citation: J Clin Invest. 1991 Oct;88(4):1362-9
references.pmid: 1918386
references.citation: N Engl J Med. 2003 Sep 18;349(12):1123-32
references.pmid: 13679526
references.citation: Crit Care. 2006;10(5):R126
references.pmid: 16956410
references.citation: Crit Care Med. 2001 Jul;29(7):1303-10
references.pmid: 11445675
references.citation: Crit Care. 2006 Feb;10(1):R33
references.pmid: 16507164
references.citation: Am J Respir Crit Care Med. 2008 Aug 1;178(3):276-82
references.pmid: 18511707
references.citation: Am J Respir Crit Care Med. 2005 May 1;171(9):995-1001
references.pmid: 15618461
references.citation: Crit Care Med. 2005 Jan;33(1):1-6; discussion 230-2
references.pmid: 15644641
references.citation: Chest. 1991 Dec;100(6):1619-36
references.pmid: 1959406
references.citation: Clin Cancer Res. 2008 Dec 15;14(24):8019-26
references.pmid: 19088018
references.citation: N Engl J Med. 2008 Nov 20;359(21):2195-207
references.pmid: 18997196
references.citation: N Engl J Med. 2004 Jul 22;351(4):327-36
references.pmid: 15269312
references.citation: Am J Respir Crit Care Med. 1997 Jan;155(1):15-20
references.pmid: 9001282
references.citation: Br Med J. 1980 Nov 15;281(6251):1336-8
references.pmid: 7437789
references.citation: Crit Care Med. 2002 Jan;30(1):1-6
references.pmid: 11902249
references.citation: Am J Respir Crit Care Med. 2003 Mar 1;167(5):695-701
references.pmid: 12433670
references.citation: Crit Care Med. 1997 Mar;25(3):405-12
references.pmid: 9118654
references.citation: Crit Care Med. 2007 Oct;35(10):2243-50
references.pmid: 17944012
references.citation: Pediatrics. 2009 Jul;124(1):87-95
references.pmid: 19564287
references.citation: Intensive Care Med. 2002 Nov;28(11):1606-12
references.pmid: 12415448
references.citation: N Engl J Med. 2009 Feb 19;360(8):816-23
references.pmid: 19228627